Finasteride vs dutasteride, and what off-label really means

Dutasteride is the other 5-alpha-reductase inhibitor. The comparison people want is which one works better; the comparison that actually governs the decision is which one a regulator has assessed for hair loss where you live, because the answer changes who carries the risk.

The pharmacological difference

There are two types of 5-alpha-reductase. The US label for finasteride describes it as a competitive and specific inhibitor of type II, with around a hundredfold selectivity for type II over type I, and attributes about two-thirds of circulating DHT to type II and roughly a third to type I. Dutasteride inhibits both types — the EMA describes both medicines as working by preventing the enzyme from converting testosterone into DHT, with dutasteride working in the same way as finasteride.

Blocking both types lowers DHT further. Whether more suppression produces proportionally more hair, and at what cost, is the question, and it is not answered by the mechanism. The mechanism page goes through what the enzyme does besides making DHT, which is the other half of the calculation.

Where each one is licensed

Finasteride holds a hair-loss licence in the US since 1997 and across the UK and EU. Dutasteride, in those same jurisdictions, is licensed for benign prostatic hyperplasia — the US labelling for the brand states its indication as symptomatic BPH, alone or with tamsulosin, and adds the limitation that it is not approved for the prevention of prostate cancer. There is no hair-loss indication in it, and no approved topical version of either molecule exists in the US — what is sold there is compounded, which brings its own problems.

Japan is the exception people cite, and it is a real one. On 4 September 2015 the Japanese Ministry of Health, Labour and Welfare concluded, on the review of the Pharmaceuticals and Medical Devices Agency, that the product could be approved with the indication "androgenetic alopecia in men" — the PMDA having found the efficacy of dutasteride in treating male pattern hair loss demonstrated and its safety acceptable in view of the observed benefits. That is a genuine licence, in one country, granted in 2015.

What off-label actually means

Outside those jurisdictions, prescribing dutasteride for hair loss is off-label. The phrase gets used as an accusation and as a reassurance, and it is neither.

• It is lawful. Prescribers may use a licensed medicine outside its licensed indication where they judge it appropriate for the patient in front of them.
• It means no regulator has assessed the medicine for that use, so the usual safeguard — an authority reviewing the evidence and writing the product information — is absent for the thing you are taking it for.
• It moves the responsibility. The prescriber carries the judgement the label would otherwise carry, which is precisely why this is not a decision to make from a website, ours included.

This is also why nothing on this site will discuss how to obtain dutasteride for hair loss. An off-label prescription is a conversation with a clinician who knows your history, or it is nothing.

Why the Japanese approval does not travel

People reasonably ask why, if one regulator assessed the evidence and approved it, the others have not simply followed. The answer is procedural rather than scientific, and it is worth knowing because it recurs across medicine.

Regulators do not review a molecule; they review an application. A company must file a dossier for a specific indication in a specific territory, pay for it and commit to the obligations that follow — the Japanese approval, for instance, came with a four-year re-examination period and a required risk management plan. Where no company has filed for a hair-loss indication, no agency has an application in front of it, and silence from a regulator is not a judgement.

So the honest reading of the Japanese licence is narrow: one authority examined a dossier and found the efficacy demonstrated and the safety acceptable for that use. It is real evidence that somebody official looked. It is not a finding that the FDA, the MHRA or the EMA have made or declined to make.

The safety record, which is thinner rather than cleaner

People sometimes read dutasteride's quieter safety file as evidence that it is gentler. The regulators say the opposite of that inference.

The European review found insufficient evidence to establish a causal association between dutasteride and suicidal ideation — and then added information about mood changes to its product information anyway, as a precautionary measure based on a possible class effect of 5-alpha-reductase inhibitors. The EU data it had was very limited: 13 cases against finasteride's 313. The UK reached the same place on 11 May 2026, adding a note that depressed mood, depression or suicidal ideation has been reported with another medicine of the same class, on the basis of 5 UK reports against finasteride's 170.

The US label lists depressed mood among post-approval reports. And in the four-year REDUCE trial, high-grade prostate cancers were found in 1.0% of men on dutasteride against 0.5% on placebo — the same signal the finasteride prevention trial produced at 1.8% against 1.1%.

What a prescriber is weighing

Not which molecule is better in the abstract. The questions that decide an off-label prescription are about the person: what has already been tried and for how long, whether the diagnosis is secure, what else is being taken, what the patient would count as an acceptable risk, and whether they will be seen again. A licence does some of that reasoning in advance and hands over a document; without one, all of it has to be done in the room.

That is why the useful preparation for such an appointment is not a printed forum thread about which inhibitor is stronger. It is a clear account of your own history and a willingness to ask what the prescriber will monitor and how often.

How to hold the comparison

Three honest statements, in order of how much weight they carry. Dutasteride suppresses DHT more completely because it blocks both enzyme types. One national regulator has assessed it for male pattern hair loss and approved it; the others have not looked. Its psychiatric safety data is thinner than finasteride's, which is a statement about how much has been reported, not about how safe it is — and both regulators that examined the question added warnings to it on class grounds.

For the licensed option and the trial figures behind it, see finasteride, start to finish. For what the warnings on both medicines are based on, read the side-effect record.